Mettler Toledo International (MTD) stock price is $1,677.28, down 2.67% on the day, as of Nov 5, 2026. It has a market cap of $33.79Bn and a P/E ratio of 37.32, and is classified in the Industrial Machinery industry (Industrials sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap33.79 Bn
P/E37.32
FCF (Yr)848.65 Mn
ROA (Yr)25.00
EV to EBIT27.28
Net Income (Yr)869.19 Mn
Enterprise Value33.55 Bn
Add ratio to table…
About
Mettler-Toledo International Inc. is a leading global supplier of precision instruments and services. The company designs manufactures and distributes laboratory instruments industrial weighing systems and retail weighing solutions. It also provides software platforms and after sales service to support its products. Its instruments are used in research development quality control and manufacturing processes across life sciences food chemicals and related industries.
The…
Mettler-Toledo International Inc. is a leading global supplier of precision instruments and services. The company designs manufactures and distributes laboratory instruments industrial weighing systems and retail weighing solutions. It also provides software platforms and after sales service to support its products. Its instruments are used in research development quality control and manufacturing processes across life sciences food chemicals and related industries.
The company generates revenue primarily from the sale of precision instruments and associated service contracts. Laboratory instruments including balances pipettes and analyzers contributed about fifty six percent of net sales in recent years. Industrial weighing and inspection products accounted for roughly thirty nine percent of net sales. Retail weighing solutions represented approximately five percent of net sales. Service offerings such as maintenance calibration and warranty contracts contributed about twenty five percent of net sales.
Mettler-Toledo International Inc. holds leading market positions in many of its product lines and claims global number one status in most of them. The company is recognized as an innovation leader with a strong record of new product introductions. Its extensive sales and service network operates in more than one hundred forty countries with a direct presence in about forty nations. Competitive advantages include a broad product portfolio a large installed base of instruments global brand reputation and diversified revenue sources across geography and industry.
The company serves a diverse customer base that includes pharmaceutical and biotechnology firms food manufacturers chemical and specialty chemicals companies cosmetics producers academic institutions food retailers transportation and logistics providers metal processors and electronics manufacturers. No single customer accounts for more than one percent of annual net sales. This diversification reduces reliance on any single end market or client.
Sectors:Industrials·HealthcareSector rationaleThe company's primary revenue comes from designing and manufacturing industrial weighing systems and retail weighing solutions, which fall under Industrial Machinery or Electrical Equipment. A substantial secondary business line exists in laboratory instruments (balances, pipettes, analyzers) sold to pharmaceutical and biotechnology firms, which aligns with Life Sciences Tools in the Healthcare sector.Industries:Industrial MachineryIndustrial MachineryPrimaryThe company manufactures industrial weighing systems and inspection products, which account for roughly 39% of net sales and are sold to manufacturers and industrial operators in sectors like food, chemicals, and metal processing.Life Sciences ToolsLife Sciences ToolsSecondaryMettler-Toledo designs and manufactures laboratory instruments, including balances, pipettes, and analyzers, which contribute approximately 56% of net sales and are used in life sciences research and development.Classified using BQ-MICSCIK: 0001037646
Bull & bear
Investment Thesis
▲ Bull case
MTD is strategically positioned to capitalize on the accelerating global shift toward automation and digitalization in manufacturing, particularly in high-growth segments such as biopharma, battery production, and semiconductor manufacturing. The company’s core Industrial segment demonstrated 5% local currency sales growth in Q1, driven by an 11% surge in product inspection and mid-single-digit momentum in China, where customers are actively investing in automation capacity to support domestic supply chain resilience and export competitiveness. Management highlighted that core industrial sales to pharma, food manufacturing, and chemical sectors represent about 60% of this business, with chemical being the softest due to energy costs—but noted that biopharma and food manufacturing remain robust, and the automation pipeline is improving despite only a 1.5-month typical backlog. The launch of innovative products like the M50 R-Series metal detector with 20% sensitivity gain and the EasyMax automated reactor directly addresses unmet demand for precision, throughput, and regulatory compliance in these sectors, creating a self-reinforcing cycle of innovation-driven market share gains. Crucially, MTD’s service attach rate is growing organically at 5% (excluding acquisitions), with dedicated initiatives to increase connectivity across its installed base—many of which are not yet under service contracts—offering a high-margin, recurring revenue stream that remains underappreciated by the market. The company’s R&D investment of $51 million (up 1% local currency) continues to yield tangible product differentiation, as evidenced by its leadership in PFAS-free pipette tips and dual-energy X-ray solutions, which not only meet evolving regulatory demands but also justify premium pricing. With full-year 2026 local currency sales guidance reaffirmed at approximately 4% (including 1.5% acquisition contribution in H1) and adjusted EPS raised to $46.30–$46.95 (8%-10% growth), MTD is pricing in a conservative outlook that does not fully reflect the potential for second-half acceleration from improving pipeline KPIs, China’s mid-single-digit growth upgrade, and the tailwinds from onshoring and nearshoring trends in the U.S. and Europe. The market appears to be overlooking the structural durability of MTD’s innovation moat and the scalability of its service business, which together could drive margin expansion beyond current guidance if macro uncertainty eases faster than anticipated.
MTD is strategically positioned to capitalize on the accelerating global shift toward automation and digitalization in manufacturing, particularly in high-growth segments such as biopharma, battery production, and semiconductor manufacturing. The company’s core Industrial segment demonstrated 5% local currency sales growth in Q1, driven by an 11% surge in product inspection and mid-single-digit momentum in China, where customers are actively investing in automation capacity to support domestic supply chain resilience and export competitiveness. Management highlighted that core industrial sales to pharma, food manufacturing, and chemical sectors represent about 60% of this business, with chemical being the softest due to energy costs—but noted that biopharma and food manufacturing remain robust, and the automation pipeline is improving despite only a 1.5-month typical backlog. The launch of innovative products like the M50 R-Series metal detector with 20% sensitivity gain and the EasyMax automated reactor directly addresses unmet demand for precision, throughput, and regulatory compliance in these sectors, creating a self-reinforcing cycle of innovation-driven market share gains. Crucially, MTD’s service attach rate is growing organically at 5% (excluding acquisitions), with dedicated initiatives to increase connectivity across its installed base—many of which are not yet under service contracts—offering a high-margin, recurring revenue stream that remains underappreciated by the market. The company’s R&D investment of $51 million (up 1% local currency) continues to yield tangible product differentiation, as evidenced by its leadership in PFAS-free pipette tips and dual-energy X-ray solutions, which not only meet evolving regulatory demands but also justify premium pricing. With full-year 2026 local currency sales guidance reaffirmed at approximately 4% (including 1.5% acquisition contribution in H1) and adjusted EPS raised to $46.30–$46.95 (8%-10% growth), MTD is pricing in a conservative outlook that does not fully reflect the potential for second-half acceleration from improving pipeline KPIs, China’s mid-single-digit growth upgrade, and the tailwinds from onshoring and nearshoring trends in the U.S. and Europe. The market appears to be overlooking the structural durability of MTD’s innovation moat and the scalability of its service business, which together could drive margin expansion beyond current guidance if macro uncertainty eases faster than anticipated.
MTD faces significant near-term headwinds from persistent customer caution in Western markets, particularly in the chemical sector and academic research, which are eroding organic growth and pressuring margins despite superficial top-line strength. The company reported flat local currency sales in the Laboratory segment (excluding acquisitions and currency), with pipette demand softening due to reduced spending from academia and biotech customers—a trend management acknowledged as tied to broader caution in Western markets, not transient factors. This weakness is compounded by food retail segment volatility, where U.S. sales declined double digits in Q1, offset only by strong Europe performance, indicating lumpy and unpredictable demand that undermines forecasting reliability. Gross margin declined 80 basis points year-over-year, with unfavorable currency and acquisitions dragging down performance, and incremental tariffs contributing a 90 basis point headwind to operating margin and reducing operating profit by 4%—a direct hit to profitability that management admits is not fully offset by price realization (which contributed only 3.5% in Q1 and is guided to 2.5% for the year). While management cites improving pipeline KPIs and China momentum as second-half catalysts, they explicitly admitted they lack quantification for customer order delays, revealing a critical blind spot in their ability to predict conversion timing. The chemical sector’s softness, driven by higher energy costs in Europe linked to Middle East instability and Ukraine-related energy pressures, is causing customers to delay capital expenditures and facility expansions—a structural, not cyclical, drag that could persist given the prolonged nature of geopolitical tensions and energy transition costs. Furthermore, MTD’s guidance assumes a return to prior IEEPA tariff levels in the second half of 2026, excluding potential refunds, which introduces significant uncertainty; if tariffs remain elevated or rebound unexpectedly, the 90 basis point margin headwind could persist or worsen, undermining EPS growth targets. The company’s reliance on acquisition-driven growth (1.5% in H1, <1% for full year) to bolster reported growth masks stagnant organic trends, particularly in Laboratory and core Industrial segments, where growth is flat to low single-digit on an organic basis. With SG&A and R&D both rising at 1% local currency—reflecting ongoing investments without commensurate organic sales leverage—operating efficiency is under pressure, and the market may be overestimating the durability of MTD’s pricing power in the face of weakening end-market demand. The raised EPS guidance of $46.30–$46.95 appears aggressive given the confluence of tariff uncertainty, currency volatility, and persistent softness in high-exposure segments like chemical and academia, suggesting the market is underestimating the risk of guidance cuts if macro conditions fail to improve as hoped.
MTD faces significant near-term headwinds from persistent customer caution in Western markets, particularly in the chemical sector and academic research, which are eroding organic growth and pressuring margins despite superficial top-line strength. The company reported flat local currency sales in the Laboratory segment (excluding acquisitions and currency), with pipette demand softening due to reduced spending from academia and biotech customers—a trend management acknowledged as tied to broader caution in Western markets, not transient factors. This weakness is compounded by food retail segment volatility, where U.S. sales declined double digits in Q1, offset only by strong Europe performance, indicating lumpy and unpredictable demand that undermines forecasting reliability. Gross margin declined 80 basis points year-over-year, with unfavorable currency and acquisitions dragging down performance, and incremental tariffs contributing a 90 basis point headwind to operating margin and reducing operating profit by 4%—a direct hit to profitability that management admits is not fully offset by price realization (which contributed only 3.5% in Q1 and is guided to 2.5% for the year). While management cites improving pipeline KPIs and China momentum as second-half catalysts, they explicitly admitted they lack quantification for customer order delays, revealing a critical blind spot in their ability to predict conversion timing. The chemical sector’s softness, driven by higher energy costs in Europe linked to Middle East instability and Ukraine-related energy pressures, is causing customers to delay capital expenditures and facility expansions—a structural, not cyclical, drag that could persist given the prolonged nature of geopolitical tensions and energy transition costs. Furthermore, MTD’s guidance assumes a return to prior IEEPA tariff levels in the second half of 2026, excluding potential refunds, which introduces significant uncertainty; if tariffs remain elevated or rebound unexpectedly, the 90 basis point margin headwind could persist or worsen, undermining EPS growth targets. The company’s reliance on acquisition-driven growth (1.5% in H1, <1% for full year) to bolster reported growth masks stagnant organic trends, particularly in Laboratory and core Industrial segments, where growth is flat to low single-digit on an organic basis. With SG&A and R&D both rising at 1% local currency—reflecting ongoing investments without commensurate organic sales leverage—operating efficiency is under pressure, and the market may be overestimating the durability of MTD’s pricing power in the face of weakening end-market demand. The raised EPS guidance of $46.30–$46.95 appears aggressive given the confluence of tariff uncertainty, currency volatility, and persistent softness in high-exposure segments like chemical and academia, suggesting the market is underestimating the risk of guidance cuts if macro conditions fail to improve as hoped.